Biohaven Pharmaceutical Holding Reaches Analyst Target Price
nasdaq.com
news
2022-06-03 07:32:00

In recent trading, shares of Biohaven Pharmaceutical Holding Co Ltd (Symbol: BHVN) have crossed above the average analyst 12-month target price of $145.80, changing hands for $145.99/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher â€” if things are looking up for the company, perhaps it is time for that target price to be raised.
